These appointments follow the departures of André de Villers and Jacques
Stock symbol: TSX: TOS
Outstanding shares: 72,888,182
QUEBEC CITY, March 20, 2013 /CNW Telbec/ - Mr. Germain Carrière,
Chairman of the Board of TSO3 Inc. ("TSO3") (TSX: TOS), is pleased to announce the appointment of Mr. Claude
Michaud and Mr. Jean Lamarre to the Board of Directors, following the
departures of long standing members Dr. André de Villers and
Dr. Jacques Marcotte.
Claude Michaud is an experienced finance executive and investment
banker. He has a 15-year career in investment banking with Scotia
Capital and TD Securities, and has been Chief Financial Officer of
C-MAC Industries, Neurochem, Kangaroo Media and Groupe Lagassé. Mr.
Michaud brings to the Board his expertise in corporate finance, mergers
and acquisitions and corporate development. He is member of the Board
of Directors of Milit-Air and the Fondation du Théatre du
Nouveau-Monde. He is a past member of the Board of Andromed, the
Investment Dealers Association (Quebec), the Board of Trade of
Metropolitan Montreal and the Women's Y Foundation. Mr. Michaud is a
member of the Order of Engineers of Quebec and holds a Bachelor in
engineering from McGill University and a MBA from Cornell University.
Jean Lamarre has more than 35 years of experience in international
business development, finance, and corporate strategy. He is President
of Lamarre Consultants, a global advisory firm in connection with
strategic development, financing and international operations. Mr.
Lamarre has been the Executive Chairman of the Board of Semafo, Inc
since June 2008. He has been a Director of Semafo Inc. since May 1997
and served as its Lead Director from February 2004 to June 2008. Mr.
Lamarre is also the Chairman of the Board of Tele-Québec and the daily
newspaper Le Devoir. He serves as a Director of Centre québécois de
valorisation des biotechnologies, Klox Technologies, Mispro Biotech
Services, Argos Therapeutics and other private or non-profit
organizations. From 1993 to 1995, Mr. Lamarre served as Vice-President
International and Special Projects at the Canam Manac Group. Prior to
that, he was head of European operations at SNC-Lavalin and held
various management positions, including Chief Financial Officer, of
Lavalin Inc before it merged with the SNC Group to form SNC-Lavalin.
He holds a Bachelor of Business Administration with a major in Applied
Economics from HEC Montreal.
"TSO3 is pleased to welcome Mr. Claude Michaud and Mr. Jean Lamarre as our
newest Board members", said Mr. Carrière, Chairman of the Board.
"Claude brings to the Board expertise in finance, merger and
acquisitions, as well as governance, while Jean has an impressive
track-record in the areas of international business development,
finance and corporate strategy. These newest members provide additional
depth to our Board and will surely be an asset to the company and its
shareholders at this exciting time in the Company's history. I would
also like to take this opportunity to acknowledge and thank Dr. André
de Villers and Dr. Jacques Marcotte, for their involvement and guidance
as Board members respectively for fourteen and twelve years."
"I am pleased to be joining the Board of TSO3", stated Claude Michaud. "TSO3 is uniquely positioned to address the need for sterilization of complex
and challenging medical devices, in a fast-growing industry", he added.
"It makes for an exciting time to contribute as a Board Member and
witness what is coming next".
"TSO3 provides to the industry and to a potential strategic partner both
superior product offering and capability to further innovate", stated
Jean Lamarre. "It is an exciting time to be joining the Board of TSO3 and I couldn't be more pleased with the opportunity."
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument
sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital
environment and offers an advantageous replacement solutions to other
low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts (including, without
limitation, those regarding the timing or outcome of any financing
undertaken by TSO3) are forward-looking statements that involve certain risks,
uncertainties and hypotheses, including, but not limited to, general
business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other risks and
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
SOURCE: TSO3 Inc.
For further information:
Director - Investor and Business Relations
418 651-0003, Ext. 237